Ionis (IONS) Q2 FY26 earnings call

Ionis Pharmaceuticals reported strong Q2 FY26 results, driven by robust commercial performance of TRYNGOLZA and DAWNZERA, and significant R&D revenue. The company is advancing its wholly-owned and partnered pipeline, with key regulatory and clinical milestones expected in the second half of the year, including the launch of Zilganerse and potential approval of Bepirovirsen. Despite a setback with the eplontersen Cardio Transform study, Ionis reaffirmed its full-year 2026 financial guidance and its commitment to achieving cash flow breakeven by 2028.